Search Results

1. Persyst 15 EEG Review and Analysis Software is intended for the review, monitoring and analysis of EEG recordings made by electroencephalogram (EEG) devices to aid neurologists in the assessment of EEG. This device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.
2. The Seizure Detection and Seizure Probability component of Persyst 15 is intended to mark previously acquired sections of the adult (greater than or equal to 18 years) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with a full scalp montage according to the standard 10/20 system. Alternatively, the Seizure Detection can operate using reduced set of electrodes including Fp1, F7, T3, O1, Fp2, F8, T3, T6, O2, but will have decreased sensitivity for seizures due to its limited spatial sampling.
3. The Neonatal Seizure Detection component of Persyst 15 is intended to mark previously acquired sections of neonatal patients' (defined as near-term or term neonates of conceptional age between 36 and 44 weeks and less than two weeks of chronologic age) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with scalp-recorded EEG using the standard International 10-20 system electrode placement, modified for neonates (this includes electrode sites Fp1/2 or alternate F1/2, C3/4, T3/4, O1/2, and Cz, optionally including Fz). Alternatively, the Neonatal Seizure Detection component can operate using a more reduced set of electrodes including C3/4, Fp1/2 (F1/2), and O1/2 (recorded in such a manner to allow creation of montage C3-4, Fp1-O1, Fp2-O2), or an even more simplified electrode set including only C3/4 and Cz (arranged as C3-Cz and C4-Cz), but the three-electrode montage will have decreased sensitivity for seizures due to its limited spatial sampling.
4. The Spike Detection component of Persyst 15 is intended to mark previously acquired sections of the patient's EEG recordings that may correspond to spikes, in order to assist qualified clinical practitioners in the assessment of EEG traces. The Spike Detection component is intended to be used in patients at least one month old. Persyst 15 Spike Detection performance has not been assessed for intracranial recordings.
5. Persyst 15 EEG Review and Analysis Software includes the Persyst Imaging Workflow (PW), an imaging viewer. It is intended for use by qualified clinical practitioners on both adult and pediatric subjects at least 12 years of age to interpret EEG data in conjunction with any type of neuroimaging including magnetic resonance imaging (MRI) or computed tomography scans (CT). Persyst Imaging Workflow is not intended to provide diagnostic information.
6. The Persyst ESI component of Persyst 15 is intended for use by a trained/qualified EEG technologist or physician on both adult and pediatric subjects at least 3 years of age for the visualization of human brain function by fusing a variety of EEG information with rendered images of an individualized head model and an individualized MRI image.
7. The Persyst 15 sleep state feature provides the user with output concerning wake-sleep states (wake or sleep,) present in an EEG recording as an aid in assessing which states are present and when they are present. The EEG being assessed for sleep state should utilize standard 10-20 system electrode recording positions and contain the expected EEG patterns of typical wake and sleep, with no major persistent pathological alterations. The sleep state output is subject to user confirmation via EEG waveform review and is not intended for the diagnosis of sleep disorders (e.g.: sleep apnea, narcolepsy, restless leg syndrome). The sleep state feature is intended for adult and pediatric subjects at least 13 years and older.
8. Persyst 15 includes the calculation and display of a set of quantitative measures intended to monitor and analyze the EEG waveform. These include FFT, Rhythmicity, Peak Envelope, Artifact Intensity. Amplitude. Relative Symmetry, and Suppression Ratio. Automatic event marking is not applicable to quantitative measures. These quantitative EEG measures should always be interpreted in conjunction with review of the original EEG waveforms.
9. Persyst 15 displays physiological signals, including the calculation and display of a heart rate measurement based on the ECG channel in the EEG recording, which are intended to aid in the analysis of an EEG. Heart rate measurement of Persyst 15 is not applicable to patients with pacemaker and/or active implantable devices.
10. The aEEG functionality included in Persyst 15 is intended to monitor the state of the brain. The automated event marking function of Persyst 15 is not applicable to aEEG.
11. Persyst 15 provides notifications for seizure detection, quantitative EEG and aEEG that can be used when processing a record during acquisition. These include an on screen display and the optional sending of an email message. Delays of up to several minutes can occur between the beginning of a seizure and when the Persyst 15 notifications will be shown to a user. Persyst 15 notifications cannot be used as a substitute for real time monitoring of the underlying EEG by a trained expert.
12. Persyst 15 AR (Artifact Reduction) is intended to reduce EMG, eye movement, and electrode artifacts in a standard 10-20 EEG recording. AR does not remove the entire artifact signal, and is not effective for other types of artifacts. AR may modify portions of waveforms representing cerebral activity. Waveforms must still be read by a qualified medical practitioner trained in recognizing artifact, and any interpretation or diagnosis must be made with reference to the original waveforms.
13. This device does not provide any diagnostic conclusion about the patient's condition to the user.

Not Found

Ask a specific question about this device

1. Persyst 15 EEG Review and Analysis Software is intended for the review, monitoring and analysis of EEG recordings made by electroencephalogram (EEG) devices to aid neurologists in the assessment of EEG. This device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.

2. The Seizure Detection and Seizure Probability component of Persyst 15 is intended to mark previously acquired sections of the adult (greater than or equal to 18 years) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with a full scalp montage according to the standard 10/20 system.

3. The Neonatal Seizure Detection component of Persyst 15 is intended to mark previously acquired sections of neonatal patients' (defined as near-term or term neonates of conceptional age between 36 and 44 weeks of chronologic age) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with scalp-recorded EEG using the standard International 10-20 system electrode placement, modified for neonates (this includes electrode sites Fp1/2 or alternate F1/2, C3/4, T3/4, O1/2, and Cz, optionally including Fz). Alternatively, the Neonatal Seizure Detection component can operate using a more reduced set of electrodes including C3/4, Fp1/2 (F1/2), and O1/2 (recorded in such a manner to allow creation of montage C3-4. Fp1-01, Fp2-02), or an even more simplified electrode set including only C3/4 and Cz (arranged as C3-Cz and C4-Cz), but the three-electrode montage will have decreased sensitivity for seizures due to its limited spatial sampling."

4. The Spike Detection component of Persyst 15 is intended to mark previously acquired sections of the patient's EEG recordings that may correspond to spikes, in order to assist qualified clinical practitioners in the assessment of EEG traces. The Spike Detection component is intended to be used in patients at least one month old. Persyst 15 Spike Detection performance has not been assessed for intracranial recordings.

5. Persyst 15 EEG Review and Analysis Software includes the Persyst Imaging Workflow (PIW), an imaging viewer. It is intended for use by qualified clinical practitioners on both adult and pediatric subjects at least 12 years of age to interpret EEG data in conjunction with any type of neuroimaging including magnetic resonance imaging (MRI) or computed tomography scans (CT). Persyst Imaging Workflow is not intended to provide diagnostic information.

6. The Persyst ESI component of Persyst 15 is intended for use by a trained/qualified EEG technologist or physician on both adult and pediatric subjects at least 3 years of age for the visualization of human brain function by fusing a variety of EEG information with rendered images of an individualized head model and an individualized MRI image.

7. The Persyst 15 sleep state feature provides the user with output concerning wake or sleep) present in an EEG recording as an aid in assessing which states are present. The EEG being assessed for sleep state should utilize standard 10-20 system electrode recording positions and contain the expected EEG patterns of typical wake and sleep, with no major persistent pathological alterations. The sleep state output is subject to user confirmation via EEG waveform review and is not intended for the diagnosis of sleep disorders (e.g.: sleep apnea, narcolepsy, restless leg syndrome). The sleep state feature is intended for adult and pediatric subjects at least 13 years and older

8. ThePersyst 15 includes the calculation and display of a set of quantitative measures intended to monitor and analyze the EEG waveform. These include FFT, Rhythmicity, Peak Envelope, Artifact Intensity, Amplitude, Relative Symmetry, and Suppression Ratio. Automatic event marking is not applicable to the quantitative measures. These quantitative EEG measures should always be interpreted in conjunction with review of the original EEG waveforms.

9. The Persyst 15 displays physiological signals, including the calculation and display of a heart rate measurement based on the ECG channel in the EEG recording, which are intended to aid in the analysis of an EEG. Heart rate measurement of Persyst 15 is not applicable to patients with pacemaker and/or active implantable devices.

10. The aEEG functionality included in Persyst 15 is intended to monitor the state of the brain. The automated event marking function of Persyst 15 is not applicable to aEEG.

11. The Persyst 15 provides notifications for seizure detection, quantitative EEG and aEEG that can be used when processing a record during acquisition. These include an on screen display and the optional sending of an email message. Delays of up to several minutes can occur between the beginning of a seizure and when the Persyst 15 notifications will be shown to a user. Persyst 15 notifications cannot be used as a substitute for real time monitoring of the underlying EEG by a trained expert.

12. The Persyst 15 AR (Artifact Reduction) is intended to reduce EMG, eye movement, and electrode artifacts in a standard 10-20 EEG recording. AR does not remove the entire artifact signal, and is not effective for other types of artifacts. AR may modify portions of waveforms representing cerebral activity. Waveforms must still be read by a qualified medical practitioner trained in recognizing artifact, and any interpretation or diagnosis must with reference to the original waveforms.

13. This device does not provide any diagnostic conclusion about the patient's condition to the user.

Not Found

The provided text is a 510(k) clearance letter from the FDA for the Persyst 15 EEG Review and Analysis Software. It does not contain information about acceptance criteria, device performance study results, sample sizes, expert qualifications, or adjudication methods for a medical device. This letter primarily outlines the device's intended uses and confirms its substantial equivalence to previously marketed devices.

Therefore, I cannot fulfill your request for a table of acceptance criteria and reported device performance or details about the study that proves the device meets the acceptance criteria, as this information is not present in the provided document.

Ask a specific question about this device

1. Persyst 14 EEG Review and Analysis Software is intended for the review, monitoring and analysis of EEG recordings made by electroencephalogram (EEG) devices using scalp electrodes and to aid neurologists in the assessment of EEG. The device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.

2. The Seizure Detection component of Persyst 14 is intended to mark previously acquired sections of adult (greater than or equal to 18 years) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with a full scalp montage according to the standard 10/20 system.

3. The Spike Detection component of Persyst 14 is intended to mark previously acquired sections of the patient's EEG recordings that may correspond to spikes, in order to assist qualified clinical practitioners in the assessment of EEG traces. The Spike Detection component is intended to be used in patients at least one month old. Persyst 14 Spike Detection performance has not been assessed for intracranial recordings.

4. Persyst 14 includes the calculation and display of a set of qualitative measures intended to monitor and analyze the EEG waveform. These include FFT, Rhythmicty, Peak Envelope, Artifact Intensity, Amplitude, Relative Symmetry and Suppression Ratio. Automatic event marking is not applicable to the quantitative measures. These quantitative EEG measures should always be interpreted in conjunction with review of the original EEG waveforms.

5. Persyst 14 displays physiological signals, including the calculation and display of a heart rate measurement based on the ECG channel in the EEG recording, which are intended to aid in the analysis of an EEG. Heart rate measurement of Persyst 14 is not applicable to patients with pacemaker and/or active implantable devices.

6. The aEEG functionality included in Persyst 14 is intended to monitor the state of the brain. The automated event marking function of Persyst 14 is not applicable to aEEG.

7. Persyst 14 provides notifications for seizure detection, quantitative EEG and aEEG that can be used when processing a record during acquisition. These include an on screen display and the optional sending of an email message. Delays of up to several minutes can occur between the beginning of a seizure and when the Persyst 14 notifications will be shown to a user. Persyst 14 notifications cannot be used as a substitute for real time monitoring EEG by a trained expert.

8. Persyst AR (Artifact Reduction) is intended to reduce EMG, eye movement, and electrode artifacts in a standard 10-20 EEG recording. AR does not remove the entire artifact signal, and is not effective for other types of artifacts. AR may modify portions of waveforms representing cerebral activity. Waveforms must still be read by a qualified medical practitioner trained in recognizing artifact, and any interpretation or diagnosis must be made with reference to the original waveforms.

9. This device does not provide any diagnostic conclusion about the patient's condition to the user.

Not Found

The provided text is an FDA 510(k) clearance letter for the Persyst 14 EEG Review and Analysis Software. It states the indications for use but does not contain the specific acceptance criteria or details of the study that proves the device meets those criteria.

Therefore, I cannot provide the requested information from this document. The document primarily focuses on the regulatory clearance for the device and its intended uses. Details about internal validation studies, acceptance criteria, sample sizes, and expert qualifications are typically found in the Premarket Notification (510(k)) submission itself, which is not included here.

Ask a specific question about this device

1. The Persyst Mobile App is a software application that can be executed on a mobile platform. It is capable of displaying the original EEG data, and quantitative analysis of EEG data generated by the Persyst EEG Review and Analysis Software. This Mobile App is intended to be used by qualified medical practitioners who will exercise professional judgement in using the information.

2. This device does not provide any diagnostic conclusion about the patient's condition to the user.

The Persyst Mobile App is a software application that can be executed on a mobile platform. It is capable of displaying the original EEG data, and quantitative analysis of EEG data generated by the Persyst EEG Review and Analysis Software.

The provided text is a 510(k) clearance letter for the Persyst Mobile App, which is software for displaying and analyzing EEG data. It does not contain information about specific acceptance criteria, a study proving those criteria were met, sample sizes, data provenance, expert qualifications, adjudication methods, MRMC studies, standalone performance, training set details, or how ground truth was established.

The document states:

• Device Name: Persyst Mobile App
• Indications for Use:
  1. A software application executable on a mobile platform.
  2. Capable of displaying original EEG data and quantitative analysis of EEG data generated by Persyst EEG Review and Analysis Software.
  3. Intended for use by qualified medical practitioners who will exercise professional judgment.
  4. Does not provide any diagnostic conclusion about the patient's condition to the user.
• Regulation Number: 21 CFR 882.1400 (Electroencephalograph)
• Regulatory Class: Class II

Because this is a 510(k) clearance letter, it confirms substantial equivalence to a predicate device. It does not typically detail the specific performance validation studies that would contain the requested information about acceptance criteria or study methodologies. Such details would usually be found in the 510(k) submission itself, which is not included here. Therefore, I cannot provide the requested information from the given text.

Ask a specific question about this device

1. Persyst 13 EEG Review and Analysis Software is intended for the review, monitoring and analysis of EEG recordings made by electroencephalogram (EEG) devices using scalp electrodes and to aid neurologists in the assessment of EEG. This device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.

2. The Seizure Detection component of Persyst 13 is intended to mark previously acquired sections of adult (greater than or equal to 18 years) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG traces. EEG recordings should be obtained with a full scalp montage according to the standard 10/20 system.

3. The Spike Detection component of Persyst 13 is intended to mark previously acquired sections of the patient's EEG recordings that may correspond to spikes, in order to assist qualified clinical practitioners in the assessment of EEG traces. The Spike Detection component is intended to be used in patients at least one month old. Persyst 13 Spike Detection performance has not been assessed for intracranial recordings.

4. Persyst 13 includes the calculation and display of a set of quantitative measures intended to monitor and analyze the EEG waveform. These include FFT, Rhythmicity, Peak Envelope, Artifact Intensity, Amplitude, Relative Symmetry and Suppression Ratio. Automatic event marking is not applicable to the quantitative measures. These quantitative EEG measures should always be interpreted in conjunction with review of the original EEG waveforms.

5. The aEEG functionality included in Persyst 13 is intended to monitor the state of the brain. The automated event marking function of Persyst 13 is not applicable to aEEG.

6. Persyst 13 provides notifications for seizure detection, quantitative EEG that can be used when processing a record during acquisition. These include an on screen display and the optional sending of an email message. Delays of up to several minutes can occur between the beginning of a seizure and when the Persyst 13 notifications will be shown to a user. Persyst 13 notifications cannot be used as a substitute for real time monitoring EEG by a trained expert.

7. Persyst AR (Artifact Reduction) is intended to reduce EMG, eye movement, and electrode artifacts in a standard 10-20 EEG recording. AR does not remove the entire artifact signal, and is not effective for other types of artifacts. AR may modify portions of waveforms representing cerebral activity. Waveforms must still be read by a qualified medical practitioner trained in recognizing artifact, and any interpretation or diagnosis must be made with reference to the original waveforms.

8. This device does not provide any diagnostic conclusion about the patient's condition to the user.

Not Found

Here's an analysis of the provided text to fulfill your request, focusing on acceptance criteria and supporting studies for the Persyst 13 device.

It's important to note that the provided document is a 510(k) clearance letter and an "Indications for Use" statement. It does not contain the detailed study results or explicit acceptance criteria tables that would typically be found in a full submission or a clinical trial report. The FDA 510(k) clearance process primarily evaluates substantial equivalence to a legally marketed predicate device rather than requiring de novo efficacy studies with specific performance metrics and acceptance criteria.

Therefore, the response below will extract what can be inferred or found directly from the text and highlight what information is not present.

Acceptance Criteria and Device Performance Study (Based on Provided Document)

The provided document (FDA 510(k) clearance letter K151929 for Persyst 13) is a regulatory approval, not a detailed scientific study report. As such, it does not explicitly state specific acceptance criteria (e.g., minimum sensitivity, specificity, or AUC thresholds) or present a table of quantitative performance metrics from a clinical study. The FDA's 510(k) clearance process relies on demonstrating "substantial equivalence" to a predicate device, which implies the device performs at least as well as, or comparably to, the predicate.

The document indicates that certain components of Persyst 13 have specific intended functionalities, for which performance would have been assessed to support the 510(k) submission. However, the actual performance values or the detailed study design (including acceptance criteria) are not included in this public-facing clearance letter.

We can infer the types of performance relevant to the device's claims, specifically for "Seizure Detection" and "Spike Detection."

Table 1: Acceptance Criteria (Inferred from Indications for Use) and Reported Device Performance (Not Stated in Document)

Study Information (Where Available or Inferable from the Document)

Since the document does not provide a detailed study report, much of the requested information is not explicitly stated. Where information can be inferred or is directly mentioned, it is noted.

1. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

   • Not explicitly stated in the document. The document is a regulatory clearance, not a study report. Details about the test set size, data origin, or whether it was retrospective/prospective would be in the original 510(k) submission, which is not provided.
   • Implicitly, for Seizure Detection: "previously acquired sections of adult (greater than or equal to 18 years) EEG recordings."
   • Implicitly, for Spike Detection: "previously acquired sections of the patient's EEG recordings... in patients at least one month old." Performance for intracranial recordings was not assessed.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

   • Not explicitly stated in the document. This level of detail would be in the study design section of the 510(k) submission. However, the "Indications for Use" repeatedly mentions "qualified medical practitioners," "neurologists," and "trained expert" as the intended users and interpreters, implying that ground truth would be established by such qualified individuals, likely neurologists or epileptologists.

3. Adjudication method (e.g. 2+1, 3+1, none) for the test set

   • Not explicitly stated in the document.

4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

   • Not explicitly stated in the document. The device is cleared as an assistive tool ("to aid neurologists," "to assist qualified clinical practitioners"). This phrasing implies that human readers are still central to the interpretation. Whether a formal MRMC study was done to quantify improvement with AI assistance is not described in this clearance letter.

5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

   • Yes, implicitly. The "Seizure Detection" and "Spike Detection" components "mark previously acquired sections." This implies an algorithm-only function to identify and highlight these events, which are then presented to a human for review. The indications for use emphasize that the device does not provide diagnostic conclusions and is intended to assist practitioners, suggesting the algorithm's output is not final without human review.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

   • Inferred to be expert consensus/review of EEG waveforms. For seizure and spike detection, the most common ground truth in EEG analysis is expert annotation by neurologists or epileptologists. The document explicitly states that quantitative EEG measures "should always be interpreted in conjunction with review of the original EEG waveforms," and for AR, "any interpretation or diagnosis must be made with reference to the original waveforms." This strongly suggests that human interpretation of raw EEG is the ultimate ground truth.

7. The sample size for the training set

   • Not explicitly stated in the document.

8. How the ground truth for the training set was established

   • Not explicitly stated in the document. As with the test set, it's highly probable it involved expert annotation of EEG data.

Summary of Document Limitations:

The provided document is an FDA clearance letter and an "Indications for Use" statement. It serves to inform that the device has been deemed substantially equivalent to a predicate and what its approved uses are. It does not typically contain the detailed technical and clinical study reports that would include specific acceptance criteria, performance metrics, sample sizes, ground truth methodologies, or granular study results (like those from MRMC studies for AI effect size). Such detailed information would reside in the original 510(k) submission document, which is not publicly available in this format.

Ask a specific question about this device

I. Persyst 12 EEG Review and Analysis Software is intended for the review, monitoring and analysis of EEG recordings made by electroencephalogram (EEG) devices using scalp electrodes and to aid neurologists in the assessment of EEG. This device is intended to be used by qualified medical practitioners who will exercise professional judgment in using the information.

2. The Seizure Detection and Seizure Probability component of Persyst 12 is intended to mark previously acquired sections of adult (greater than or equal to 18 years) EEG recordings that may correspond to electrographic seizures, in order to assist qualified clinical practitioners in the assessment of EEG tecordings should be obtained with a full scalp montage according to the standard 10/20 system.

3. The Spike Detection component of Persyst 12 is intended to mark previously acquired sections of the patient's EEG recordings that may correspond to spikes, in order to assist qualified cinical practitioners in the assessment of EEG traces. The Spike Detection component is intended to be used in patients at least one month old. Persyst 12 Spike Detection performance has not been assessed for intracranial recordings.

4. Persyst 12 includes the calculation and display of a set of quantitative measures intended to monitor and analyze the EEG waveform. These include FFT, Rhythmicity, Peak Envelope, Artifact Intensity, Amplinde, Relative Symmetry and Suppression Ratio. Automatic event marking is not applicative measures. These quantitative EEG measures should always be interpreted in conjunction with review of the original EEG waveforms.

5. The aEEG functionality included in the Persyst 12 is intended to monitor the brain. The automated event marking function of Persyst 12 in not applicable to aEEG.

6. Persyst 12 provides notifications for seizure detection, quantitative EEG that can be used when processing a record during acquisition. These include an on screen display and the optional sending of an email message. Delays of up to several minutes can occur between the beginning of a seizure and when the Persyst 12 notifications will be shown to a user. Persyst 12 notifications cannot be used as a substitute for real time monitoring of the underlying EEG by a trained expert.

7. Persyst AR (Artifact Reduction) is intended to reduce EMG, eye movement, and electrode artifacts in a standard 10-20 EEG recording, AR does not remove the entifact signal, and is not effective for other types of artifacts. AR may modify portions of waveloms representing cerebral activity. Waveforms must still be read by a qualified medical practitioner trained in recognizing artifact, and any interpretation or diagnosis must be made with reference to the original waveforms.

8. This device does not provide any diagnostic conclusion about the patient's condition to the user.

Not Found

The provided document is limited to the FDA's 510(k) clearance letter and the Indications for Use for the Persyst 12 EEG Review and Analysis Software. It does not contain the detailed study information, acceptance criteria, or performance data that would allow for a complete answer to the request.

Therefore, I cannot provide a table of acceptance criteria vs. device performance, sample sizes, expert qualifications, adjudication methods, MRMC study details, standalone performance, ground truth types, or training set information based solely on the provided text.

The document only states that the device is "substantially equivalent" to predicate devices, and outlines its intended uses:

• Overall Intent: Review, monitoring, and analysis of EEG recordings to aid neurologists in assessment.
• Seizure Detection and Seizure Probability: Marks previously acquired sections of adult (≥18 years) EEG recordings that may correspond to electrographic seizures.
• Spike Detection: Marks previously acquired sections of patient's EEG recordings that may correspond to spikes, for patients at least one month old.
• Quantitative Measures: Calculates and displays quantitative measures (FFT, Rhythmicity, Peak Envelope, Artifact Intensity, Amplitude, Relative Symmetry, Suppression Ratio) for monitoring and analysis.
• aEEG functionality: Monitors the brain.
• Notifications: Provides notifications for seizure detection and quantitative EEG, but emphasizes these are not a substitute for real-time monitoring.
• Artifact Reduction (AR): Intended to reduce EMG, eye movement, and electrode artifacts in standard 10-20 EEG recordings.

To properly answer your request, the actual 510(k) submission summary or a separate clinical study report would be required.

Ask a specific question about this device